GlassScriptPhysician profile
Amit B Patel
NPI 1316208093
$19,243.04
in general payments reported to CMS, 2019-2025
52 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $1,930 · 2021: $2,876 · 2022: $2,511 · 2023: $3,867 · 2024: $4,443 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,566 · Travel and Lodging: $2,444 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,565.57 |
| Travel and Lodging | $2,444.29 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,453.26 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Janssen Pharmaceuticals, INC | $2,449.41 | 2019-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $2,243.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $2,025.41 | 2021-2025 | |
| Pacira Pharmaceuticals Incorporated | $1,201.73 | 2023 | Iovera |
| Novo Nordisk INC | $1,093.41 | 2019-2025 | Ozempic, Wegovy, Saxenda |
| Bayer Healthcare Pharmaceuticals INC. | $875.22 | 2021-2025 | |
| Lilly USA, LLC | $726.63 | 2020-2024 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.46 | 2019-2024 | Ofev, Jardiance, Stiolto Respimat |
| Sumitomo Pharma America, INC. | $506.10 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $367.85 | 2021-2025 | Freestyle Libre 3, Eterna |
| Esperion Therapeutics, INC. | $296.24 | 2020-2025 | Nexletol |
| Mylan Specialty L.P. | $287.62 | 2022-2024 | Yupelri |
| Dexcom, INC. | $282.79 | 2020-2023 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $273.30 | 2024-2025 | Ibsrela |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.